↓ Skip to main content

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma

Overview of attention for article published in Frontiers in immunology, October 2021
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
18 Mendeley